Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocriplasmin - Oxurion

Next Previous
Drug Profile

Ocriplasmin - Oxurion

Alternative Names: A-01016; Jejetrea®; Jetrea; Microplasmin; Recombinant human microplasmin; Recombinant microplasmin; THR-409

Latest Information Update: 22 Jan 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Leuven
  • Developer Alcon; Oxurion; ThromboGenics; University of Leuven
  • Class Anti-ischaemics; Eye disorder therapies; Peptide fragments; Serine endopeptidases
  • Mechanism of Action Antiplasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal disorders; Peripheral arterial occlusive disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Marketed Retinal disorders
  • Phase II Diabetic retinopathy
  • Suspended Deep vein thrombosis; Peripheral arterial occlusive disorders; Stroke
  • No development reported Retinal vein occlusion
  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 05 Jan 2021 ThromboGenics and Wagner Macula and Retina Center terminates the phase II TOTEM trial for Retinal disorders (Vitreomacular traction) in USA (Intravitreous) (NCT04300881)
  • 12 Mar 2020 Ocriplasmin licensed to Inceptua Medicine worldwide for commercialisation
  • 04 Oct 2019 ThromboGenics and Wagner Macula and Retina Center initiates enrolment in the phase II TOTEM trial for Retinal disorders (Vitreomacular traction) in USA (Intravitreous) (NCT04300881)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top